Open Access

PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial‑mesenchymal transition

  • Authors:
    • Hongyu Liu
    • Min Wang
    • Na Liang
    • Lianyue Guan
  • View Affiliations

  • Published online on: January 15, 2019     https://doi.org/10.3892/mmr.2019.9860
  • Pages: 2173-2179
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epithelial-mesenchymal transition (EMT) has an established role in the acquisition of therapeutic resistance. Programmed cell death domain 2 (PDCD2) is involved in the progression of multiple types of cancer. However, its mechanism underlying chemoresistance in liver cancer has not been elucidated. In the present study, it was demonstrated that the sorafenib‑resistant HepG2 cell line exhibited EMT and multidrug resistance (MDR) phenotypes, and reduced expression of PDCD2, by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), western blot analysis and Cell Counting Kit‑8. Annexin V/fluorescein isothiocyanate and cell migration assays further demonstrated that PDCD2 effectively promoted sorafenib‑induced cell apoptosis and reduced cell metastasis. Mechanistically, PDCD2 inhibited the expression of Vimentin and increased the expression of E‑cadherin in a Snail‑dependent manner by RT‑qPCR and western blot analysis. In conclusion, the present study elucidated for the first time, to the best of our knowledge, that PDCD2 sensitizes sorafenib‑resistant HepG2 cells to sorafenib by the downregulation of EMT. PDCD2 may serve as a potential therapeutic target in the treatment of sorafenib‑resistant liver cancer.
View Figures
View References

Related Articles

Journal Cover

March-2019
Volume 19 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu H, Wang M, Liang N and Guan L: PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial‑mesenchymal transition. Mol Med Rep 19: 2173-2179, 2019
APA
Liu, H., Wang, M., Liang, N., & Guan, L. (2019). PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial‑mesenchymal transition. Molecular Medicine Reports, 19, 2173-2179. https://doi.org/10.3892/mmr.2019.9860
MLA
Liu, H., Wang, M., Liang, N., Guan, L."PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial‑mesenchymal transition". Molecular Medicine Reports 19.3 (2019): 2173-2179.
Chicago
Liu, H., Wang, M., Liang, N., Guan, L."PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial‑mesenchymal transition". Molecular Medicine Reports 19, no. 3 (2019): 2173-2179. https://doi.org/10.3892/mmr.2019.9860